change to version of title

Is de novo a realistic regulatory pathway? Or, the “kiss of death” for your product? No, to de novo? Think again. Who cares about de novo? We do! Today’s guest is “Dr. De Novo “(a.k.a. Mike Drues of Vascular Sciences), who describes how to make de novo a viable option for your medical device. 





Like this episode? Subscribe today on iTunes or SoundCloud.


Some of the highlights of the show include:

  • For years, use of de novo was rare; fewer than five devices were brought to market. MDUFA stats state FDA received 56 de novos in 2018; 18 in 2019.
  • Congress deserves credit for changing the law to make de novos more attractive to companies. De novo nuances became less problematic and challenging.
  • Mike’s public prediction in 2012 came true. De novo pathway has increased in importance, popularity, and usage; but still pale in comparison to 510(k).
  • De novo is advantageous option for medical device technology, especially mobile medical apps, imaging, and in-vitro diagnostics (IVDs).
  • Rather than focusing on options from a regulatory pathway, analyze and account for who at the agency will be the recipient due to their de novo experience.
  • 510(k) vs. De Novo: Is device new and novel? Or, similar in technology and labeling to another device on the market?
  • De Novo: Applicable for lower than Class III medical devices; 510(k) requires substantial equivalence and risk; de novo only needs risk mitigation strategy.
  • FDA’s review time of de novo submissions average six to eight months, while 510(k) submissions take three to four months.



De Novo Pathway: Explaining the Process for Medical Device Companies

Advanced Strategies and Tactics for Using the De Novo Pathway

Guest Editorial: The de novo pathway – strategies and tactics to use and avoid

Secrets Of The De Novo Pathway, Part 1: Why Aren't More Device Makers Using It?

Secrets Of The De Novo Pathway, Part 2: Is De Novo Right For Your Device?

FDA De Novo Program

FDA Premarket Notification 510(k)

MedTech True Quality Stories Podcast

Drug Industry Association (DIA)

Medical Device User Fee Amendments (MDUFA)


Mike Drues

Greenlight Guru


Quotes by Mike drues:

“For the first decade or so of the de novo’s life, it was used very infrequently. That is obviously changing." 

“We have to give Congress credit. They changed the law to make de novos much more attractive to companies.”

“Any monkey can see a trend...where were all these people five years ago predicting the trend, before that data was observable?”

“The numbers of the de novo, although they are higher, they still pale in comparison to the 510(k).”



The Global Medical Device Podcast powered by Greenlight Guru is where today's brightest minds in the medical device industry go to get their most useful and actionable insider knowledge, direct from some of the world's leading medical device experts and companies.

Like this episode? Subscribe today on iTunes or SoundCloud.